NSCLC

[Scientific Reports] Secondary cisplatin resistance majorly undermines the cisplatin efficacy leading to a worse prognosis. In this respect, researchers identified the role of the DLX6-AS1/miR-181a-5p/miR-382-5p/CELF1 axis in regulating cisplatin resistance of lung squamous cell carcinoma.

[Cell Death & Disease] Scientists evaluated the function of golgi phosphoprotein 3 (GOLPH3) in non-small-cell lung cancer (NSCLC) distal metastasis. GOLPH3 was expressed at high levels in samples from patients with NSCLC and was positively associated with clinicopathologic characteristics including clinical stage classification.

[Nature Communications] Hypothesizing that EGFR mutations alter tumor-immune interactions, scientists compared tumor-infiltrating lymphocytes between EGFR mutant and wild type tumors through single-cell transcriptomic analysis.

[ESMO Open] In this review, the post-osimertinib treatment options for EGFR-mutated non-small-cell lung cancer are analyzed, with an outlook to ongoing clinical trials.

[Journal of Experimental & Clinical Cancer Research] Researchers found that SETD1A positively regulated the Wnt/β-catenin pathway via interacting with and stabilizing β-catenin.

[Aging] Cell functional experiments revealed that lncRNA DARS-AS1 participated in enhancing lung adenocarcinoma proliferation, invasion, and migration by inhibiting miR-188-5p.